There is no denying the fact that ephedra diet pills were extremely popular. Millions of people both men and women alike used ephedra safely for over 10 years to help them with burning more fat and losing weight. Thereby regaining some of their health that doctors tell us is due to being overweight.
First established by scientific proof and then backed up by use in the bodybuilding world. During competition use of ephedra helped bodybuilders lose additional fat and then consumers in the real world found that it helped them also.
People certainly do not continously use a product for year after year if it doesn't work. The fat loss effects of ephedra were real, sometimes dramatic but certainly not made up advertising.
Ephedra diet pills were proven to help shed approximately ten pounds a month without additional changes in diet or exercise. That meant that a person who ate properly and exercised could lose more weight in a month's time. Of course some people reacted differently and were not able to lose that kind of weight.
It seems okay for the drug companies to sell killer pain pills for years, hidding the evidence and then being allowed to bring the very same pills back onto the market with a tiny print warning. But ephedra that was hardly any risk at all during more than a decade of use gets slapped around and removed like it was a certain killer of thousands.
There were 5 studies examined that showed that ephedrine alone compared to a placebo produced a significant weight loss of 1.3 pounds per month more than the placebo. But when it is combined with caffeine (as shown in 12 studies) the weight loss jumped to 2.2 pounds per month when compared against a placebo.
It should be noted that in 52 clinical trials with ephedrine or ephedra, these randomized controlled trials produced no serious adverse events such as seizure, stroke, death, or serious psychiatric events. There was evidence produced that there was an increased possibility of minor events such as anxiety or mood changes, palpitations, nausea and vomiting.